Original-Research: Aiforia Technologies Oyj - from NuWays AG 11.05.2026 / 09:00 CET/CEST Dissemination of a Research, transmitted by EQS News - a service of EQS Group. The issuer is solely responsible for the content of this research. The result of this research does not constitute investment advice or an invitation to conclude certain stock exchange transactions.
Classification of NuWays AG to Aiforia Technologies Oyj
| Company Name: | Aiforia Technologies Oyj |
| ISIN: | FI4000507934 |
| |
| Reason for the research: | Update |
| Recommendation: | BUY |
| Target price: | EUR 3.8 |
| Target price on sight of: | 12 months |
| Last rating change: | |
| Analyst: | Julius Neittamo |
Strong cross-read from Roche's PathAI takeover Last week, Roche announced the acquisition of PathAI for up to $ 1.05bn ($ 750m upfront, $ 300m in earnouts), to be integrated into its Diagnostics division. PathAI is privately held, and few valuation details are provided in connection with the deal. PathAI divested its lab services business to Quest Diagnostics for $ 100m in June 2024. Post-divestment, this could put PathAI's FY25 sales at a range of $ 30-40m, implying a deal valuation of 26-35x sales (incl. earnouts). At Friday close, Aiforia traded at 18.3x EV/S FY25 and 12.4x EV/S FY26 (eNuW).
A strong catalyst for the market. Significant M&A moves from large healthtech players typically signal that a new technology has reached commercial viability at scale. The hefty premium paid here indicates that
current revenue levels do not reflect the long-term potential of AI in oncology diagnostics. Consolidation is picking up pace, something we flagged as a strong possibility in our initiation note from October.
Aiforia is a compelling pure-play in AI pathology as Aiforia (i) is an early mover, having internally developed market leading AI models, (ii) possesses Tier-1 clinical customers, (iii) has the regulatory runway to scale and (iv) the recently launched Foundation Engine is seen to expedite the path to profitability. Notably, Clinical revenue grew organically 68% yoy in H2'25, accelerating sequentially from 60% yoy in H1.
Aggregate growth in FY26 is seen accelerating to 70% yoy, with Clinical sales doubling yoy (eNuW).
Large healthtech companies are betting big on AI. In this context, Aiforia stands out as the leading AI play in clinical oncology diagnostics. We make no changes to our DCF model, and reiterate our
BUY rating with a
€ 3.80 PT. You can download the research here:
aiforia-technologies-oyj-2026-05-11-update-en-1abef For additional information visit our website:
https://www.nuways-ag.com/research Contact for questions: NuWays AG - Equity Research Web: www.nuways-ag.com Email: research@nuways-ag.com LinkedIn: https://www.linkedin.com/company/nuwaysag Adresse: Mittelweg 16-17, 20148 Hamburg, Germany ++++++++++ Diese Meldung ist keine Anlageberatung oder Aufforderung zum Abschluss bestimmter Börsengeschäfte. Offenlegung möglicher Interessenkonflikte nach § 85 WpHG beim oben analysierten Unternehmen befindet sich in der vollständigen Analyse. ++++++++++
The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. View original content: EQS News
Aufrufe: 70
